Microdosing in Phase O: A Q&A with J. Scott Tarrant, Xceleron - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Microdosing in Phase O: A Q&A with J. Scott Tarrant, Xceleron
J. Scott Tarrant, executive vice-president of Xceleron, explains the role of microdosing in drug development. He describes how microdose data can be used to predict pharmacological dose absorption, distribution, metabolism, and excretion/pharmacokinetic outcomes using accelerator mass spectrometry.


Pharmaceutical Technology


References

1. FDA, Guidance for Industry, Investigators and Reviewers. Exploratory IND Studies including Human Microdose Studies (Rockville, MD, Jan. 2006).

2. European Medicines Agency, "Position Paper on Nonclinical Safety Studies to Support Clinical Trials with a Single Microdose" (London, June 23, 2004).

3. EUMAPP, "European Union Microdose AMS Partnership Program (EUMAPP) Background Paper" (York, UK, Jan. 2006).

4. G. Lappin et al., "Use of Microdosing to Predict Pharmacokinetics at the Therapeutic Dose: Experience with Five Drugs," Clin. Pharmacol. Ther. 80 (3), 203–215 (2006).

5. G. Lappin and R.C. Garner, "Big Physics, Small Doses: The Use of AMS and PET in Human Microdosing of Development Drugs," Nat. Rev. Drug Dis. 2 (3), 233–240 (2003).

6. P. Sandhu et al., "Evaluating of Microdosing Strategies for Studies in Preclinical Drug Development: Demonstration of Linear Pharmacokinetics in Drugs of a Nucleoside Over a 50-Fold Dose Range," Drug Metab. Dispos. 32 (11), 1254–1259 (2004).

7. S.K. Balani et al, "Evaluation of Microdosing to Assess Pharmacokinetic Linearity in Rats Using Liquid Chromatography–Tandem Mass Spectrometry," Drug Metab. Dispos. 34 (3), 384–388 (2006).

8. N. Yamane et al, "Microdose Clinical Trial: Quantitative Determination of Fexofenadine in Human Plasma Using Liquid Chromatography/Electrospray Ionization Tandem Mass Spectrometry," J. Chromatogr., B. Analyt. Technol. Biomed Life Sci. 858 (1–2), 118–128 (2007).

9. Le.T. Vuong et al., "Use of Accelerator Mass Spectrometry to Measure the Pharmacokinetics and Peripheral Blood Mononuclear Cell Concentrations of Zidovudine," J. Pharm. Sci. 97 (7), 2833–2843 (2007).

10. Z. O'Brien, "Using Microdosing and AMS Analysis to Compare Clinical Pharmacokinetics of Four Development Drugs with Diphenhydramine," presented at AAPS Annual Meeting, San Diego, CA, Nov., 2007.

11. Speedel, "SPP635," (Basel, Switzerland), http:// http://www.speedel.com/section/4/subsections/5/, accessed July 14, 2008.

12. J. Ni et al., "Microdosing Assessment to Evaluate Pharmacokinetics and Drug Metabolism in Rats using Liquid Chromatography-Tandem Mass Spectrometry," Pharm. Res. 25 (7), 1572–1582 (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here